Biblio Discovery — Demo Discovery Service

9 results for "Kate E. Foley"

Showing 1–9 · 0.38 seconds · RSS

  1. Journal Article

    Three major effects of APOEε4 on Aβ immunotherapy induced ARIA

    Kate E. Foley; Donna M. Wilcock

    Frontiers in Aging Neuroscience, Vol. 16 · 2024 · English · DOAJ Scopus

    The targeting of amyloid-beta (Aβ) plaques therapeutically as one of the primary causes of Alzheimer’s disease (AD) dementia has been an ongoing effort spanning decades. While some antibodies are extremely promising and have been moved out of clinical trials and into the clinic, most of these…

  2. Journal Article

    Acute anti‐Aβ antibody exposure induces microglial changes and significantly alters chemokine signaling

    Kate E. Foley; Erica M. Weekman; Donna M. Wilcock

    Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol. 12 No. 1 · 2026 · English · DOAJ Scopus

    Abstract INTRODUCTION While the anti‐amyloid‐lowering immunotherapies provide the first disease‐targeting therapies for the treatment of Alzheimer's disease, there remain harmful adverse events causing hesitation among patients, families, physicians, and regulatory bodies. Though these drugs have…

  3. Journal Article

    Transcriptional profiling predicts running promotes cerebrovascular remodeling in young but not midlife mice

    Kate E. Foley; Hongtian Stanley Yang; Leah C. Graham et al.

    BMC Genomics, Vol. 20 No. 1 · 2019 · English · DOAJ Scopus

    Abstract Background The incidence of dementia and cognitive decline is increasing with no therapy or cure. One of the reasons treatment remains elusive is because there are various pathologies that contribute to age-related cognitive decline. Specifically, with Alzheimer’s disease, targeting to…

  4. Journal Article

    APOE ε4 and exercise interact in a sex‐specific manner to modulate dementia risk factors

    Kate E. Foley; Cory A. Diemler; Amanda A. Hewes et al.

    Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol. 8 No. 1 · 2022 · English · DOAJ Scopus

    Abstract Introduction Apolipoprotein E (APOE) ε4 is the strongest genetic risk factor for Alzheimer's disease and related dementias (ADRDs), affecting many different pathways that lead to cognitive decline. Exercise is one of the most widely proposed prevention and intervention strategies to…

  5. Journal Article

    The APOEε3/ε4 Genotype Drives Distinct Gene Signatures in the Cortex of Young Mice

    Kate E. Foley; Amanda A. Hewes; Dylan T. Garceau et al.

    Frontiers in Aging Neuroscience, Vol. 14 · 2022 · English · DOAJ Scopus

    IntroductionRestrictions on existing APOE mouse models have impacted research toward understanding the strongest genetic risk factor contributing to Alzheimer’s disease (AD) and dementia, APOEε4, by hindering observation of a key, common genotype in humans – APOEε3/ε4. Human studies are typically…

  6. Journal Article

    A novel mouse model expressing human forms for complement receptors CR1 and CR2

    Harriet M. Jackson; Kate E. Foley; Rita O’Rourke et al.

    BMC Genetics, Vol. 21 No. 1 · 2020 · English · DOAJ

    Abstract Background The complement cascade is increasingly implicated in development of a variety of diseases with strong immune contributions such as Alzheimer’s disease and Systemic Lupus Erythematosus. Mouse models have been used to determine function of central components of the complement…

  7. Journal Article

    Uncovering Disease Mechanisms in a Novel Mouse Model Expressing Humanized APOEε4 and Trem2*R47H

    Kevin P. Kotredes; Adrian Oblak; Ravi S. Pandey et al.

    Frontiers in Aging Neuroscience, Vol. 13 · 2021 · English · DOAJ Scopus

    Late-onset Alzheimer’s disease (AD; LOAD) is the most common human neurodegenerative disease, however, the availability and efficacy of disease-modifying interventions is severely lacking. Despite exceptional efforts to understand disease progression via legacy amyloidogenic transgene mouse models…